Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China

Shanghai Pharmaceuticals has signed a Memorandum of Understanding with BIOCAD, Russia's largest biotech company, to form JVs that manufacture and develop BIOCAD's biologic drugs for the China market. BIOCAD plans to include at least six of its novel biologics and biosimilar drugs for cancer and immunology in the agreements. One of the JVs will include a mAb manufacturing facility. BIOCAD says it has signed export contracts worth over $850 million in the last few years, supplying its biologic medications to 14 countries. More details....

Stock Symbol: (SHA: 601607)

Share this with colleagues:

Original Article: Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China

More From BioPortfolio on "Shanghai Pharma Signs MOU to Develop BIOCAD's mAb Portfolio in China"